TD Cowen Reiterates a Buy Rating on Boston Scientific Corporation (BSX)

Boston Scientific Corporation (NYSE:BSX) is one of the best strong buy healthcare stocks to buy now. On July 23, TD Cowen analyst Josh Jennings maintained a Buy rating on Boston Scientific Corporation (NYSE:BSX) and set a price target of $115.00, supporting the rating with the company’s positive outlook and solid financial performance.

The analyst told investors that Boston Scientific Corporation’s (NYSE:BSX) Q2 2025 sales and EPS exceeded market expectations. EPS for the quarter was $0.75 and sales reached $5.06 billion, surpassing estimates of $0.73 and $4.89 billion, respectively. Jennings attributed this notable performance to a solid organic sales growth of 17.4%, considerably higher than the company’s guidance of 13-15%.

The firm further reasoned that Boston Scientific Corporation (NYSE:BSX) raised its guidance for 2025, and now expects EPS in the range of $2.95-$2.99 and organic sales growth of 14-15%.

Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments.

The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.